#United States #New York #Class Action #Iovance Biotherapeutics #IOVA

Iovance Biotherapeutics Class Action Lawsuit Alert

Overview

On May 19, 2025, Bronstein, Gewirtz & Grossman, LLC, a well-known law firm, announced the filing of a class action lawsuit related to Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). This lawsuit targets the company and specific officers due to alleged violations of federal securities laws. Investors who suffered significant losses from their Iovance investments between May 9, 2024, and May 8, 2025, are encouraged to join this legal action.

Details of the Class Action

The lawsuit's foundation lies in the claim that Iovance misled investors with overly optimistic statements while simultaneously hiding detrimental information regarding the true state of its growth potential. Notably, the concern centers around the company’s lack of preparedness to effectively meet existing demand for its treatments through its network of approved treatment centers.

On May 8, 2025, Iovance disclosed its first-quarter financial results for 2025, revealing a significant decline in product revenue. The reported total product revenue plummeted to $49.3 million, down from a previous quarter's $73.7 million—a stark indication of the company’s downward momentum. Furthermore, Iovance drastically revised its full-year financial projections, slashing its guidance from an expected range of $450 million to $475 million down to a mere $250 million to $300 million. This reduction represents a shocking drop of over 40% at the midpoint.

In light of the released financial data, Iovance’s stock faced a steep decline in value, exacerbated by unusually high trading volumes on the day of the announcement. This situation has undoubtedly raised concerns among investors about the future viability of the company’s lead product, Amtagvi® (lifileucel), which was launched commercially in the U.S. in early 2024.

Next Steps for Investors

Investors who believe they qualify for participation in this class action can find more information at the firm’s website, bgandg.com/IOVA. Additionally, they can contact the law firm's representatives for a copy of the lawsuit and further inquiries about becoming a lead plaintiff. The deadline for requesting lead plaintiff status is July 14, 2025. It's crucial to note that participation in any recovery does not require serving as a lead plaintiff.

Legal Representation on a Contingency Basis

Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning investors will not incur any costs unless the lawsuit is successful. The firm will seek reimbursement for out-of-pocket expenses and attorney fees only from successful recoveries.

Why Choose Bronstein, Gewirtz & Grossman?

Being a nationally recognized firm specializing in securities fraud class actions and shareholder derivative suits, Bronstein, Gewirtz & Grossman has successfully recovered hundreds of millions of dollars on behalf of investors nationwide. Their commitment to transparency and dedication to achieving favorable outcomes make them a reliable choice for affected investors seeking justice.

Investors can keep abreast of updates regarding the lawsuit by following the firm on professional social media platforms such as LinkedIn, X (formerly Twitter), Facebook, or Instagram. It’s essential for affected individuals to act promptly to safeguard their rights and seek possible compensation due to the financial losses incurred.

In conclusion, participants in this class action lawsuit have a chance to take a stand against corporate mismanagement while aiming for recovery of losses linked to the unfortunate series of events surrounding Iovance Biotherapeutics. It highlights the importance of vigilance in investor communications and the responsibility of companies to provide accurate disclosures.